Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 19, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in DNA can help explain why some patients develop nerve problems (called peripheral neuropathy) after receiving a specific chemotherapy drug called paclitaxel for breast cancer. By studying DNA samples from patients who have experienced these nerve issues, researchers hope to find important biological markers that can help identify why some people are affected while others are not. This knowledge could lead to better treatments or preventative measures in the future.

To participate in this trial, you need to be either a European American or African American patient who has available DNA samples and has experienced certain levels of peripheral neuropathy during paclitaxel treatment. Specifically, this trial is looking for patients who had moderate to severe nerve issues while on treatment but did not experience these problems after completing their chemotherapy. If you qualify and decide to join, you will help contribute to important research that could improve care for future breast cancer patients receiving similar treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • European American patients with DNA available and designated case or control
• • African American patients with DNA available and designated case or control status
• • Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel